Subcutaneous Ocrelizumab, Ofatumumab 'Reassuring' in MS

Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.

Related Keywords

Baltimore ,Maryland ,United States ,Nevada ,Johns Hopkins University ,Milan ,Lombardia ,Italy ,Bristol Myers Squibb ,Leh Hua ,Scottd Newsome ,Las Vegas ,Bristol Meyers Squibb ,Julie Fiol ,Lundbeck ,Roche Ltd ,Us National Ms Society ,Serono ,Brain Health ,National Ms Society ,Stiff Person Syndrome Center ,Research In Multiple Sclerosis ,Stiff Person Syndrome Research Foundation ,Novartis ,Patient Centered Outcomes Research Institute ,Department Of Defense ,Cleveland Clinic Lou Ruvo Center ,Americas Committee For Treatment ,European Committee For Treatment ,Genentech ,Joint European Committee ,Multiple Sclerosis ,Americas Committee ,Expanded Disability Status Scale ,Clinical Innovation ,Medscape Medical ,Greenwich Biosciences ,Horizon Therapeutics ,Patient Centered Outcomes Research ,Multiple Sclerosis Americas Committee ,Multiple Sclerosis Ms ,Us ,Monoclonal Antibody ,Etuximab ,Ituximab ,Clinical Research ,Clinical Trials ,Linical Studies ,Intravenous Iv ,Intravenous ,Tv ,Biologic Therapy ,Europe ,European ,Multiple Sclerosis Relapse ,S Relapse ,Elapse Of Multiple Sclerosis ,Elapse Of Ms ,Stiff Person Syndrome ,Eigg ,Brain ,Medical Innovations ,Nnovations In Medicine ,Primary Progressive Multipl ,